Company: CWAN
Filing Date: 2025-04-17
Form Type: 425
Source: 0001193125-25-083584
Chunk: 5

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-04-17
Form: 425
Chunk 5
---
-----|:----|:----|:----|:------------------------------------|
|                      |     |     |     | Jim Cox, Chief Financial Officer    |

Exhibit 99.1 FOR IMMEDIATE RELEASE Clearwater Analytics and Enfusion Announce Preliminary Results of Election by Enfusion Shareholders Regarding Form of Merger Consideration BOISE, Idaho, and CHICAGO, Illinois – April 17, 2025— Clearwater Analytics (NYSE: CWAN) (“Clearwater”) and Enfusion, Inc. (NYSE: ENFN) (“Enfusion”) today announced the preliminary results of the elections made by Enfusion shareholders of record regarding the form of merger consideration (the “Merger Consideration”) they wish to receive in connection with Clearwater’s acquisition of Enfusion (the “Transaction”). As previously disclosed, the deadline to have made such an election was 5:00 p.m. Eastern Time on April 16, 2025 (the “Election Deadline”). The parties expect to close the Transaction on April 21, 2025, subject to the approval of the Transaction by Enfusion shareholders and the satisfaction or waiver of other customary closing conditions. As previously disclosed, on January 10, 2025, Enfusion, Clearwater, Enfusion Ltd. LLC (“Enfusion OpCo”), Poseidon Acquirer, Inc. (the “Acquirer”), Poseidon Merger Sub I, Inc. and Poseidon Merger Sub II, LLC entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement and as further described in the election materials and in the parties’ definitive proxy statement/prospectus dated March 20, 2025, as supplemented by Supplement No. 1 thereto dated March 31, 2025 (as supplemented, the “Proxy Statement/Prospectus”), at the effective time of the Transaction (the “Effective Time”), each Enfusion shareholder will be entitled to receive, for each (i) share of Class A common stock of Enfusion outstanding as of immediately prior to the Effective Time, (ii) restricted stock unit of Enfusion that is vested as of immediately prior to the Effective Time or that will vest as a result of the consummation of the Transaction and (iii) limited liability company unit of Enfusion OpCo outstanding as of immediately prior to the Effective Time, in each case subject to proration according to the terms of the Merger Agreement to the extent any election is